Breaking News

First Wave BioPharma Rebrands to Entero Therapeutics

The name change follows the recent business combination with ImmunogenX.

Author Image

By: Charlie Sternberg

Associate Editor

First Wave BioPharma Inc., a late clinical-stage biopharmaceutical company, has changed its name to Entero Therapeutics Inc. and unveiled a new website.   The rebranding follows the recent business combination with ImmunogenX and reflects the company’s focus on addressing unmet needs in GI health that include celiac disease, an indication for which there are no approved medicines today.   Entero’s common stock will commence trading on May 17, 2024, on the Nasdaq Capital Market under the new ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters